Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUCMSC-derived exosome inhalation dose-escalation and dose-effect study in ARDS
ChiCTR2400091226Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital, School of Medicine, Tongji University
- Start
- Oct 2024
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cell-derived exosomes in acute respiratory distress syndrome (ARDS) (8 cohorts), sponsored by Shanghai East Hospital, School of Medicine, Tongji University. Primary endpoints: Maximum tolerated dose, Inhalation-related adverse events and 2 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell-derived exosomes
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2400091226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091226.